CBD vs CBG
CBD and CBG are both non-intoxicating cannabis compounds. This guide compares their chemistry, the evidence behind each, safety questions, and what labels can and cannot tell you.
Content last updated . This page has not been medically reviewed.
Quick answer
CBD (cannabidiol) and CBG (cannabigerol) are both cannabinoids from the cannabis plant that are not known to cause a "high" like THC. They differ mainly in how much is known. CBD has one FDA-approved prescription medicine and years of research. CBG has only a handful of small human studies. This page compares them and gives no advice on use. The owner of this site does not sell cannabis products.Evidence labels used here: approved medicine means a regulator approved a specific drug; promising but limited means early positive signals from few studies; insufficient evidence means too few good studies to conclude; marketing claim means the statement comes from sellers.
Where they come from
CBG's acid form, CBGA, is called the "mother cannabinoid" because the plant uses it to build THCA, CBDA and CBCA. [1] CBGA turns into CBG by decarboxylation, the same heat-driven change that turns CBDA into CBD. [1] CBG is among the lesser-studied cannabinoids; a 2025 review points to a gap in clinical research on it. [2] See CBG and CBD for full profiles.Evidence side by side
| Question | CBD | CBG |
|---|---|---|
| Approved medicine | Epidiolex, a purified CBD product, is FDA-approved for seizures in Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. [3] Label: approved medicine (that product only). | None found in the sources I read. |
| Human studies | Many; see CBD. | One 2024 crossover trial in 34 healthy adults used a study amount of 20 mg hemp-derived CBG or placebo and reported reductions in anxiety and stress after the product, plus better verbal memory, with no sign of impairment. [4] Label: promising but limited. |
| Safety data | NIDA lists drowsiness, decreased appetite, vomiting and diarrhea as possible side effects. [5] NCCIH adds liver injury and drug interactions. [6] | In a 2026 study of 12 healthy adults given single study amounts from 25 to 200 mg, no drug-related adverse events occurred, effects were minimal and liver tests stayed in range after single doses; chronic studies are still needed. [7] |
| How the body handles it | CBD is the best studied; absorption varies with dose, formulation, route and diet. [2] | Same review: CBG, CBC and their acids have a gap in clinical research. [2] |
These study amounts are what researchers gave volunteers. They are not recommendations.
How they act
A 2025 review found CBG, CBC and CBD bind CB1 and CB2 receptors about 10 to 100 times more weakly than THC does, and that these compounds appear to act mainly through other targets. [8] That helps explain why neither is known to be intoxicating, but it does not predict benefit.Quality and labeling
NCCIH notes that over-the-counter CBD products may contain more or less CBD than stated and may contain contaminants such as THC. [6] Products combining CBD with CBG are covered in CBD-CBG blends and CBN oils. Check a batch's certificate of analysis; see how to read a COA.Who should talk to a clinician first
Anyone who is pregnant or breastfeeding, has liver disease, or takes prescription medicines should talk with their own clinician before any cannabinoid product, because CBD has been associated with liver injury and drug interactions. [6] See CBD-medication interactions. Evidence for CBG in these groups: Proper evidence not found in the sources I checked.Legal difference
I did not read a law or regulator page about CBG specifically, so its legal status is not verified here. For CBD in food and supplements, FDA has concluded that THC and CBD products are excluded from the dietary supplement definition (read 2026-10-22). [3] Laws change and differ by place; this is not legal advice.No universal winner
They are different tools in different states of evidence. A better question is what a specific product contains and what the evidence says about that exact use.Frequently asked questions
Is CBG stronger than CBD?
That comparison has no established meaning. The two have different targets and different amounts of research. [8]
Does CBG cause a high?
In the 2024 trial, volunteers reported no subjective drug effects, and the 2026 study found minimal subjective effects. [4][7]
Can CBD or CBG treat anxiety?
CBG showed a signal in one small trial of healthy adults. [4] See cannabinoids and anxiety for what systematic reviews show.
Is CBD approved as a medicine?
Only the prescription product Epidiolex, for specific seizure disorders. [3]
Why do labels sometimes disagree with lab tests?
Studies have found that products can contain different amounts than labeled. [6]
References
- Singh SK, Antoine C, Tse C, et al. Therapeutic potential of acidic cannabinoids: an update. Journal of Cannabis Research. 2026;8(1):25. PubMed 41545891 (full text PMC12895846). Read 2026-10-22.
- Lacerda M, Carona A, Castanheira S, et al. Pharmacokinetics of Non-Psychotropic Phytocannabinoids. Pharmaceutics. 2025;17(2):236. PubMed 40006604. Abstract read 2026-10-22.
- U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). Content current as of 07/16/2024. Read 2026-10-22.
- Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Scientific Reports. 2024;14:16163. PubMed 39003387. Abstract read 2026-10-22.
- National Institute on Drug Abuse. Cannabis (Marijuana). U.S. National Institutes of Health; undated page. Read 2026-10-22.
- National Center for Complementary and Integrative Health. Cannabis (Marijuana) and Cannabinoids: What You Need To Know. Page last updated November 2019. Read 2026-10-22.
- Wolinsky D, Srungaram D, Zhang A, et al. Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults. Journal of Pharmacology and Experimental Therapeutics. 2026;393(8):104984. PubMed 42575778. Abstract read 2026-10-22.
- Queiroz CM, de Oliveira Koren L, da Silva CRP, Ribeiro S, Silva SRB. Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. Progress in Brain Research. 2025;296:1-28. PubMed 40967679. Abstract read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.